Eprogen | GenomeWeb

Eprogen

According to Matthew Kuruc, COO of PIN member ProFact Proteomics, the network aims to help smaller firms offer complete solutions similar to those increasingly provided by large instrument vendors and to popularize non-mass spec-based proteomics workflows.

Although it's too early to announce biopharma partners, the 13 companies involved in the network are hoping that their collective skills and specialties will attract companies interested in developing drugs targeted to specific proteomic markers in patients.

The group aims to provide solutions for all stages of proteomics research and address "critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling, and selective reaction monitoring."

Over the past week, OGT acquired protein-array maker Sense Proteomic, Aushon bought Thermo's SearchLight protein-array business, and Gentel and Eprogen allied to help drug makers identify new autoantibody biomarkers.

Industry Briefs

Premium

Gentel, Eprogen, Novozymes, Proteome Sciences, Pepsca, Advanced Proteome Therapeutics, AnaSpec

Gentel and Eprogen will combine their respective technologies to make whole proteome microarrays for identifying new autoantibody biomarkers.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.